Aurobindo Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 26/05/2025 ,inter alia, to consider and approve Intimation of Board meeting to be held on May 26, 2025 to consider Audited Financial Results for the fourth quarter and financial year ended March 31, 2025.

pdf

Aurobindo Pharma Ltd.

16 May 2025

1204.10

1.03%

Aurobindo Pharma's arm teams up with IMT Hyderabad for leadership development

Business Line

This program is an important step in grooming our middle managers to take on larger responsibilities with confidence and agility,' Vice President, Corporate HR, Aurobindo Pharma

Promoters unpledged 0.91% of shares in last quarter. Total pledge stands at 16.92% of promoter holdings

Aurobindo Pharma Ltd.

15 May 2025

1204.10

1.03%

Company Update

Aurobindo Pharma Ltd - 524804 - Compliances-Reg.24(A)-Annual Secretarial Compliance

BSE India

Submission of Annual Secretarial Compliance Report for the Financial Year ended March 31, 2025

pdf

Aurobindo Pharma Ltd.

13 May 2025

1204.10

1.03%

Company Update

Aurobindo Pharma Ltd - 524804 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

BSE India

Submission of press release that is being issued by the Company in connection with receipt of approval for biosimilar Zefylti from UK''s MHRA by Curateq Biologics s.r.o, a step down wholly owned subsidiary of the Company.

pdf

Aurobindo Pharma Ltd.

12 May 2025

1204.10

1.03%

Broker's call: Aurobindo Pharma (Buy)

Business Line

Motilal Oswal

Promoters unpledged 0.91% of shares in last quarter. Total pledge stands at 16.92% of promoter holdings

Aurobindo Pharma Gets 'Buy' Upgrade From Motilal Oswal On Attractive Valuations

NDTV Profit | 12 May 2025 1 more

Aurobindo Pharma Ltd.

30 Apr 2025

1204.10

1.03%

Company Update

Aurobindo Pharma Ltd - 524804 - Intimation Under Regulation 30 Of SEBI (Listing Obligations And Disclosure …

BSE India

Intimation of receipt of order from the Deputy Commissioner, Punjagutta (ST) STU-1 of GST, Punjagutta Division Hyderabad.

pdf

Aurobindo Pharma Ltd.

29 Apr 2025

1204.10

1.03%

Fire Incident halts production at Aurobindo Pharma subsidiary

Business Line

As a precautionary measure, operations at the plant will be suspended for an estimated 20 to 25 days while equipment is replaced

Aurobindo Pharma Ltd. has an average target of 1516.56 from 9 brokers.

Aurobindo Pharma Ltd.

28 Apr 2025

1204.10

1.03%

Company Update

Aurobindo Pharma Ltd - 524804 - Intimation Regarding A Safety Incident On April 27, 2025, At …

BSE India

Intimation of fire accident at Lyfius Pharma Private Limited, a wholly owned step down subsidiary of the Company.

pdf

Aurobindo Pharma Ltd.

28 Apr 2025

1204.10

1.03%

Corp. Note

Aurobindo Pharma Ltd - 524804 - Format of the Initial Disclosure to be made by an …

BSE India

Format of Initial Disclosure to be made by an entity identified as a Large Corporate. Sr. No. Particulars Details 1Name of CompanyAurobindo Pharma Ltd 2CIN NO.L24239TG1986PLC015190 3 Outstanding borrowing of company as on 31st March / 31st December, as applicable (in Rs cr) 1170.00 4Highest Credit Rating during the previous FY AA+ 4aName of the Credit Rating Agency issuing the Credit Rating mentioned in (4)INDIA RATINGS AND RESEARCH PVT. LTD. 5Name of Stock Exchange# in which the fine shall be paid, in case of shortfall in the required borrowing under the frameworkBSE We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018. YES Name of the Company Secretary: B ADI REDDY Designation: Company Secretary EmailId: cs@aurobindo.com Name of the Chief Financial Officer: SANTHANAM SUBRAMANIAN Designation: Chief Financial Officer EmailId: subramanian.santhanam@auroindo.com Date: 28/04/2025 Note: In terms para of 3.2(ii) of the circular, beginning F.Y 2022, in the event of shortfall in the mandatory borrowing through debt securities, a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore, an entity identified as LC shall provide, in its initial disclosure for a financial year, the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets.

pdf

Is Aurobindo Pharma Ltd. worth buying?

1240 Votes:

Buy 80.16%

Sell 13.79%

Hold 6.05%

RESEARCH REPORTS

Buy SEE REPORTS >

pdf

Buy SEE REPORTS >

pdf